What the FDA labels say about taking them together
Lansoprazole and nilotinib
Lansoprazole's FDA label of June 24, 2025 names nilotinib in its drug interactions (prescription label) section; nilotinib's label does not name lansoprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The lansoprazole label: “Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.”
Check it at the source: the lansoprazole FDA label on DailyMed (effective June 24, 2025, L. Perrigo Company); the nilotinib FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation).
What does the lansoprazole label say about nilotinib?
Lansoprazole label, drug interactions (prescription label)Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Coadministration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. …
Source: FDA drug label (Prevacid 24 HR), L. Perrigo Company, effective June 24, 2025 (SPL set 205c9c1e-b422-4e86-a4b0-714b608adc19), via openFDA; the full label on DailyMed
What does the nilotinib label say about lansoprazole?
Nilotinib's label does not name lansoprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Nilotinib label, drug interactionsAvoid concomitant use with Tasigna. Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors.
Nilotinib label, drug interactionsProton Pump Inhibitors Concomitant use with a proton pump inhibitor (PPI) decreased nilotinib concentrations compared to Tasigna alone [see Clinical Pharmacology (12.3)], which may reduce Tasigna efficacy.
Source: FDA drug label (Tasigna), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 6093952a-5248-45cb-ad17-33716a411146), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lansoprazole | Nilotinib | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.106 per capsule 30 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once